A Phase I, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA 720 Adjuvant in 18-45 Year Old Healthy Adults

Trial Profile

A Phase I, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA 720 Adjuvant in 18-45 Year Old Healthy Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs MVA BN YF (Primary) ; Montanide ISA-720; Smallpox vaccine; Yellow fever vaccine
  • Indications Yellow fever
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Aug 2017 Planned End Date changed from 29 Dec 2017 to 17 May 2018.
    • 10 Aug 2017 Planned primary completion date changed from 25 Jul 2017 to 29 Dec 2017.
    • 13 Jul 2017 Planned primary completion date changed from 31 Mar 2017 to 25 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top